Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This study is tracking how HyQvia is actually used in real-world settings — things like infusion rates, needle sizes, and whether patients do it at home or in a clinic — so would joining this study change anything about how I receive my HyQvia treatment, or would I essentially be continuing care as normal while my data is collected?
2. 2The trial is measuring how often infusions have to be slowed down, stopped, or switched to a different treatment — does that tell us there are known tolerability issues with HyQvia that I should understand before considering it as part of my myeloma care?
3. 3One of the things this study tracks is whether patients have caregiver support available — how much help would I realistically need at home to manage subcutaneous infusions, and is that something my current situation could support?
4. 4Since this trial has no assigned phase and is observational rather than testing a new drug, how does it differ from a standard treatment plan where my doctor simply prescribes HyQvia — and is there any reason to participate versus just receiving the treatment outside of a study?
5. 5Given that secondary immunodeficiency is common in multiple myeloma, is HyQvia already considered a standard option for my situation, or are there other approaches to managing infections and low immunoglobulin levels that we should compare it against before deciding anything?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.